Biotech boom continues with Repare’s $90 mln Series A, Zymeworks IPO
Canada’s life sciences sector is on a roll. Current levels of venture capital investment are unprecedented. This week another major deal was announced, with Repare Therapeutics, a Montréal developer of precision oncology drugs, securing about $90 million in a Series A financing. One of the sector’s other big stories is the IPO of biotherapeutics provider Zymeworks. The company, which last month raised about $86 million on the Toronto and New York exchanges, is now being talked about as Canada’s next biotech anchor company.
22 June 2017•4 mins read
